Lixte Biotechnology Holdings, Inc.

Equities

LIXT

US5393193017

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:00:01 09/07/2024 am IST			5-day change	1st Jan Change
2.3 ^USD	+4.55%		-3.80%	-2.13%

14/06	Lixte Biotechnology Holdings, Inc. to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial	CI
06/06	Lixte Biotechnology Holdings, Inc. Reports Findings Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System	CI

Lixte Biotechnology Holdings, Inc. Announces Publication Online of Phase 1 Results of its Novel Anti-Cancer Compound in Clinical Cancer Research

January 04, 2017 at 10:15 pm IST

Lixte Biotechnology Holdings, Inc. announced the publication online of Phase 1 results of its novel anti-cancer compound in Clinical Cancer Research, entitled Safety, tolerability, and preliminary activity of LB-100, an inhibitor of protein phosphatase 2A, in patients with relapsed solid tumors.

Latest news about Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc. to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial	14/06	CI
Lixte Biotechnology Holdings, Inc. Reports Findings Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System	06/06	CI
LIXTE Biotechnology Holdings, Inc. Announces Executive Changes	03/06	CI
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Lixte Biotechnology Files Up to $50 Million Mixed Shelf	24/04	MT
Sector Update: Health Care Stocks Advance Late Afternoon	28/03	MT
Top Midday Gainers	27/03	MT
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	27/03	MT
Lixte Biotechnology Holdings, Inc. Announces Publication of Pre-Clinical Data in the Online Journal	27/03	CI
LIXTE Biotechnology Holdings, Inc. Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments	21/03	CI
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03	CI
LIXTE Biotechnology Holdings, Inc. Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI	26/02	CI
Lixte Biotechnology Holdings, Inc. Announces Dosing of the First Patient in A Phase 1B/2 Clinical Trial to Assess Whether Adding Lixte?S Lb-100 to Gsk?S Programmed Death Receptor-1 (Pd-1)-Blocking Monoclonal Antibody, Dostarlimab-Gxly, May Enhance the Effectiveness of Immunotherapy in the Treatment of Ovarian Clear Cell Carcinoma	29/01	CI
Top Premarket Decliners	28/11	MT
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Certain Common Stock of Lixte Biotechnology Holdings, Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2023.	19/23/19	CI
Certain Series A Preferred Stock of Lixte Biotechnology Holdings, Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2023.	19/23/19	CI
Certain Warrants of Lixte Biotechnology Holdings, Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2023.	19/23/19	CI
Certain Options of Lixte Biotechnology Holdings, Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2023.	19/23/19	CI
Certain Options of Lixte Biotechnology Holdings, Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2023.	19/23/19	CI
Certain Series A Preferred Stock of Lixte Biotechnology Holdings, Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2023.	19/23/19	CI
Certain Warrants of Lixte Biotechnology Holdings, Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2023.	19/23/19	CI
Certain Common Stock of Lixte Biotechnology Holdings, Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2023.	19/23/19	CI
Lixte Biotechnology Extends Partnership With Netherlands Cancer Institute, Oncode Institute for Cancer Therapies Investigation	16/23/16	MT
Lixte Biotechnology Names Bas van der Baan as Chief Executive	26/23/26	MT

Chart Lixte Biotechnology Holdings, Inc.

Duration

Period

Chart Lixte Biotechnology Holdings, Inc.

More charts

Company Profile

Lixte Biotechnology Holdings, Inc. is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The Companyâs product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers. The Company encompasses that inhibitors of protein phosphatases have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. It is focused on development activities of its LB-100 series of drugs. The LB-100 series have activity against a broad spectrum of common and rarer human cancers in cell culture systems. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LIXTE BIOTECHNOLOGY HOLDINGS, INC.	-2.13%	4.95M
MODERNA, INC.	+17.09%	45.34B
LONZA GROUP AG	+42.10%	40.42B
IQVIA HOLDINGS INC.	-9.70%	37.92B
ALNYLAM PHARMACEUTICALS, INC.	+33.28%	31.75B
CELLTRION, INC.	-8.98%	27.71B
ICON PUBLIC LIMITED COMPANY	+13.37%	26.52B
UNITED THERAPEUTICS CORPORATION	+44.11%	13.96B
MEDPACE HOLDINGS, INC.	+32.33%	12.44B
BIO-TECHNE CORPORATION	-7.26%	11.26B

Other Biotechnology & Medical Research